Article
Endocrinology & Metabolism
Shangyu Chai, Ruya Zhang, Ye Zhang, Richard David Carr, Yiman Zheng, Swapnil Rajpathak, Linong Ji
Summary: This meta-analysis summarizes the effects of DPP4 inhibitors on glucagon levels in patients with type 2 diabetes mellitus (T2DM). The results show that DPP4 inhibitors can significantly reduce postprandial glucagon levels in T2DM patients.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Xi Chen, Bin Xue, Shadma Wahab, Armiya Sultan, Mohammad Khalid, Song Yang
Summary: In this study, a potential DPP4 inhibitor, SRT2183, was identified using computational methods and validated through molecular docking and molecular dynamics simulations.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
(2023)
Article
Endocrinology & Metabolism
Linong Ji, Jinmiao Lu, Leili Gao, Changjiang Ying, Jiao Sun, Jie Han, Wenhua Zhao, Yunming Gao, Kun Wang, Xin Zheng, Daosheng Xie, Juping Ding, Jiahong Zhao, Qiang Yu, Tong Wang
Summary: This study assessed the efficacy and safety of the dipeptidyl peptidase-4 inhibitor, cetagliptin, as monotherapy in Chinese patients with type 2 diabetes (T2D). The results showed that cetagliptin effectively reduced HbA1c levels, and the incidence of adverse events was similar to the placebo group. Therefore, cetagliptin monotherapy is effective and well tolerated in Chinese patients with T2D.
DIABETES OBESITY & METABOLISM
(2023)
Review
Endocrinology & Metabolism
Qizhi Tang, Weiyu Pan, Liangyue Peng
Summary: The study provides preliminary evidence regarding the similarity in the efficacy of evogliptin compared to other DPP-4i drugs, including sitagliptin and linagliptin, for managing HbA1c levels and adverse events.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Review
Endocrinology & Metabolism
Shangyu Chai, Ruya Zhang, Richard David Carr, Carolyn F. Deacon, Yiman Zheng, Swapnil Rajpathak, Jingya Chen, Miao Yu
Summary: This meta-analysis showed that DPP4 inhibitors effectively increase both fasting and postprandial GIP concentrations in T2DM patients, with consistent results in sensitivity analyses. Subgroup analyses indicated that study characteristics did not significantly impact the influence of DPP4 inhibitors on GIP levels in T2DM patients.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Endocrinology & Metabolism
Chen-Yi Wu, Chun-Ying Wu, Chung-Pin Li, Yiing-Jenq Chou, Yi-Hsian Lin, Yun-Ting Chang
Summary: This study found that diabetic patients treated with DPP4 inhibitors had a significantly increased risk of bullous pemphigoid, especially when used concurrently with insulin.
DIABETES RESEARCH AND CLINICAL PRACTICE
(2021)
Article
Immunology
Yuichiro Iwamoto, Takatoshi Anno, Katsumasa Koyama, Fumiko Kawasaki, Kohei Kaku, Koichi Tomoda, Seiko Sugiyama, Yumi Aoyama, Hideaki Kaneto
Summary: DPP-4 inhibitors are closely associated with bullous pemphigoid (BP) and may lead to disruption of immune tolerance. Checking autoimmune antibodies may be important in DPP-4i-related BP, even when symptoms improve.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Endocrinology & Metabolism
Tsuyoshi Okura, Yohei Fujioka, Risa Nakamura, Yuichi Ito, Sonoko Kitao, Mari Anno, Kazuhisa Matsumoto, Kyoko Shoji, Hiroko Okura, Kazuhiko Matsuzawa, Shoichiro Izawa, Etsuko Ueta, Masahiko Kato, Takeshi Imamura, Shin-ichi Taniguchi, Kazuhiro Yamamoto
Summary: The study suggests that treatment with DPP4i may improve insulin resistance without changing insulin secretion.
DIABETOLOGY & METABOLIC SYNDROME
(2022)
Article
Endocrinology & Metabolism
Natalia McInnes, Stephanie Hall, Irene Hramiak, Ronald J. Sigal, Ronald Goldenberg, Nikhil Gupta, Remi Rabasa-Lhoret, Manoela Braga, Vincent Woo, Farah Sultan, Rose Otto, Ada Smith, Diana Sherifali, Yan Yun Liu, Hertzel C. Gerstein
Summary: The study aimed to evaluate the remission of type 2 diabetes after a short-term intervention using insulin glargine, sitagliptin/metformin, and lifestyle approaches. The results showed that although the primary outcome was not statistically significant, the intervention group had a lower risk of relapse and a higher number of participants remaining in remission in some supplementary analyses.
Article
Cardiac & Cardiovascular Systems
Qu Chen, Dandan Jiang, Zhonggui Shan
Summary: This study investigated the effects of dipeptidyl peptidase-4 inhibitors (DPP4i) on the progression of type B intramural hematoma (IMHB) in patients with diabetes mellitus (DM). The study found that DM patients with IMHB who received DPP4i treatment had lower aorta-related mortality and a more benign progression compared to those who did not receive DPP4i or those without DM. Furthermore, a higher eosinophil count and a lower neutrophil to lymphocyte ratio (NLR) were identified as potential protective factors that may explain the therapeutic benefits of DPP4i.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Article
Endocrinology & Metabolism
Marcel H. A. Muskiet, Lennart Tonneijck, Mark M. Smits, Mark H. H. Kramer, D. Margriet Ouwens, Bolette Hartmann, Jens J. Holst, A. H. Jan Danser, Jaap A. Joles, Daniel H. van Raalte
Summary: In adults with type 2 diabetes, the dipeptidyl peptidase-4 inhibitor linagliptin did not reduce postprandial hyperfiltration compared to the sulphonylurea glimepiride. However, it appeared to increase the filtration fraction after a meal by potentially raising blood pressure or efferent arteriolar resistance.
DIABETES OBESITY & METABOLISM
(2022)
Article
Endocrinology & Metabolism
Takashi Kadowaki, Yutaka Seino, Kohei Kaku, Taro Okamoto, Miho Kameya, Asako Sato, Tomona Hirano, Nobuyuki Oshima, Ira Gantz, Edward A. O'Neill, Samuel S. Engel
Summary: The study evaluated the efficacy and safety of adding the once-weekly oral dipeptidyl peptidase-4 inhibitor omarigliptin to Japanese patients with type 2 diabetes on insulin monotherapy. Results showed significant improvement in glycemic control with good tolerability, indicating the potential benefit of once-weekly omarigliptin in this patient population.
DIABETES OBESITY & METABOLISM
(2021)
Article
Endocrinology & Metabolism
So-Hee Park, Han Eol Jeong, In-Sun Oh, Sang-Mo Hong, Sung Hoon Yu, Chang Beom Lee, Ju-Young Shin
Summary: This population-based cohort study found that compared with glimepiride, the use of evogliptin did not increase the risk of cardiovascular events, including cerebrovascular events, myocardial infarction, heart failure, transient ischaemic attack, and angina pectoris.
DIABETES OBESITY & METABOLISM
(2021)
Article
Biochemistry & Molecular Biology
Shen-Chih Wang, Xiang-Yu Wang, Chung-Te Liu, Ruey-Hsing Chou, Zhen Bouman Chen, Po-Hsun Huang, Shing-Jong Lin
Summary: Linagliptin exhibits protective effects against endothelial inflammation and microvascular thrombosis in a mouse model of sepsis, and these effects are independent of blood glucose level.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Endocrinology & Metabolism
Linong Ji, Jinmiao Lu, Leili Gao, Xiaoguang Yan, Jifang Li, Zhifeng Cheng, Lili Zhang, Junhang Tian, Ping Li, Jie Bai, Daosheng Xie, Jiahong Zhao, Juping Ding, Qiang Yu, Tong Wang
Summary: This study aimed to evaluate the efficacy and safety of cetagliptin added to metformin in Chinese patients with type 2 diabetes. The results showed that the addition of cetagliptin was more effective in glycemic control and well tolerated compared to metformin monotherapy.
DIABETES OBESITY & METABOLISM
(2023)